573 related articles for article (PubMed ID: 31792692)
21. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.
Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S
ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292
[TBL] [Abstract][Full Text] [Related]
23. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
[TBL] [Abstract][Full Text] [Related]
24. Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
Narasimhan V; Cheung F; Waters P; Peacock O; Warrier S; Lynch C; Michael M; Ramsay R; Heriot A
Surgeon; 2020 Oct; 18(5):287-294. PubMed ID: 31848069
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.
Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A
Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
27. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
29. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
[TBL] [Abstract][Full Text] [Related]
30. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
Chang SC; Fingerhut A; Chen WT
Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
[TBL] [Abstract][Full Text] [Related]
31. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
[TBL] [Abstract][Full Text] [Related]
32. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience.
Arjona-Sanchez A; Rufian-Peña S; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Briceño-Delgado J
World J Surg; 2018 Oct; 42(10):3120-3124. PubMed ID: 29691625
[TBL] [Abstract][Full Text] [Related]
33. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
[TBL] [Abstract][Full Text] [Related]
34. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of hand-assisted laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy.
Salti GI; Naffouje SA
Surg Endosc; 2019 Jan; 33(1):52-57. PubMed ID: 29926165
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
38. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes.
Robella M; Vaira M; Cinquegrana A; De Simone M
Minerva Chir; 2019 Jun; 74(3):195-202. PubMed ID: 29589675
[TBL] [Abstract][Full Text] [Related]
39. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.
Shaltiel T; Solomon D; Pletcher ER; Golas BJ; Magge DR; Sarpel U; Labow DM; Cohen NA
Surg Endosc; 2022 Aug; 36(8):6153-6161. PubMed ID: 35080674
[TBL] [Abstract][Full Text] [Related]
40. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
